ArticleFrontiers in oncology2026
Safety and efficacy of CT-guided percutaneous microwave ablation for stage I non-small cell lung cancer combined with moderate-to-severe pulmonary dysfunction.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To evaluate the safety and efficacy of microwave ablation (MWA) for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction. Methods: A retrospective study was conducted involving 1,635 patients who underwent MWA between January 2018 and December 2024. The observation group consisted of 42 patients with moderate-to-severe pulmonary dysfunction, defined as maximal voluntary ventilation (MVV) < 70% or forced expiratory volume in one second (FEV Results: The observation group had a median follow-up time of 25.5 months and a median survival period of 39 months, with 1-year and 3-year survival rates of 94.9% and 68.7%, respectively. The control group had a median follow-up time of 22 months and a median survival period of 44 months, with 1-year and 3-year survival rates of 98.1% and 72.3%, respectively. The median length of hospitalization was 6 days in both groups. The incidence of adverse reactions was 42.86% in the observation group and 33.96% in the control group, with no statistically significant difference between the two groups (p > 0.4099). In the observation group, statistically significant differences were identified with respect to smoking history, emphysema, and severe pulmonary dysfunction (p < 0.05). Univariate analysis indicated that patients with FEV Discussion: MWA represents a safe, effective, and potential alternative therapeutic option for patients with stage I NSCLC and moderate-to-severe pulmonary dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.